Markel Corp held its position in shares of Baxter International Inc. (NYSE:BAX) during the third quarter, Holdings Channel reports. The institutional investor owned 22,000 shares of the company’s stock at the end of the third quarter. Markel Corp’s holdings in Baxter International were worth $1,047,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Mycio Wealth Partners LLC increased its stake in Baxter International by 27.8% in the third quarter. Mycio Wealth Partners LLC now owns 2,250 shares of the company’s stock worth $107,000 after buying an additional 490 shares during the period. Trust Department MB Financial Bank N A increased its stake in Baxter International by 4.1% in the second quarter. Trust Department MB Financial Bank N A now owns 1,746 shares of the company’s stock worth $122,000 after buying an additional 68 shares during the period. Balentine LLC increased its stake in Baxter International by 12.6% in the second quarter. Balentine LLC now owns 3,176 shares of the company’s stock worth $144,000 after buying an additional 356 shares during the period. Checchi Capital Advisers LLC increased its stake in Baxter International by 1.9% in the second quarter. Checchi Capital Advisers LLC now owns 4,333 shares of the company’s stock worth $196,000 after buying an additional 81 shares during the period. Finally, Pioneer Trust Bank N A OR acquired a new stake in Baxter International during the second quarter worth $203,000. Institutional investors own 83.64% of the company’s stock.
Baxter International Inc. (NYSE:BAX) traded up 0.15% during trading on Monday, reaching $46.79. The company had a trading volume of 910,468 shares. The stock has a market cap of $25.45 billion, a PE ratio of 5.24 and a beta of 0.88. The company has a 50-day moving average price of $47.27 and a 200 day moving average price of $46.44. Baxter International Inc. has a 52-week low of $34.06 and a 52-week high of $50.16.
Baxter International (NYSE:BAX) last issued its quarterly earnings results on Tuesday, October 25th. The company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.45 by $0.11. The firm earned $2.56 billion during the quarter, compared to analyst estimates of $2.67 billion. Baxter International had a return on equity of 11.43% and a net margin of 48.68%. The firm’s quarterly revenue was up 2.9% on a year-over-year basis. During the same period last year, the company posted $0.41 EPS. On average, analysts anticipate that Baxter International Inc. will post $1.91 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, January 3rd. Shareholders of record on Friday, December 2nd will be paid a dividend of $0.13 per share. This represents a $0.52 dividend on an annualized basis and a yield of 1.11%. The ex-dividend date of this dividend is Wednesday, November 30th. Baxter International’s payout ratio is currently 5.83%.
Several equities analysts recently issued reports on the company. RBC Capital Markets reaffirmed a “sector perform” rating and set a $55.00 price objective (up from $50.00) on shares of Baxter International in a report on Wednesday, October 26th. Barclays PLC assumed coverage on Baxter International in a report on Thursday, September 15th. They set an “overweight” rating and a $52.00 price objective for the company. Evercore ISI reaffirmed a “buy” rating and set a $56.00 price objective (up from $52.00) on shares of Baxter International in a report on Wednesday, October 26th. Zacks Investment Research raised Baxter International from a “hold” rating to a “buy” rating and set a $53.00 price objective for the company in a report on Thursday, October 13th. Finally, Royal Bank Of Canada lifted their price objective on Baxter International from $50.00 to $55.00 and gave the stock a “sector perform” rating in a report on Wednesday, October 26th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and six have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $51.30.
Baxter International Company Profile
Baxter International Inc, through its subsidiaries, provides a portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics, and pharmacy automation, software and services.